Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition. Current treatments only aim to alleviate symptoms. There are no treatments that slow or reverse the underlying damage to the heart.
Several studies in other diseases have shown that copper imbalance is associated with heart thickening similar to HCM. In these diseases, treatment with trientine dihydrochloride, an oral medicine that increases copper elimination in urine, can reverse this thickening.
We want to find out if trientine reduces heart muscle thickening in patients with HCM. We would also like to see if it improves exercise capacity, improves heart function and reduces abnormal heart rhythms. The study will also assess how trientine works in HCM. The results from this study will be used to help us to understand the effects of trientine on the heart in patients with HCM.
TEMPEST has received all necessary initial approvals (Research Ethics Committee (REC) Medicines and Healthcare products Regulatory Agency (MHRA) Health Research Authority (HRA)) for the study to go ahead.
The study will take part in Cardiac Departments across the country. To see if your hospital is taking part in this study please go to recruiting sites.
This study has been funded by the National Institute for Health Research Efficacy and Mechanism Evaluation (EME) programme (ref: NIHR127575)
This study is sponsored by Manchester University NHS Foundation Trust and coordinated by the Liverpool Clinical Trials Centre at the University of Liverpool.
The study has been reviewed by a research ethics committee, who have agreed the study is being conducted in a correct and appropriate manner. The study has also been approved by the Medicines & Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA).
The patient recruitment figures and sites currently open.